Dupilumab for the treatment of immune checkpoint blockers' induced pruritus
- 27 July 2023
- journal article
- letter
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (12) , E1475-E1476
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced MelanomaCancers, 2023
- Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer PatientsBritish Journal of Dermatology, 2022
- Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literatureDermatology Online Journal, 2021
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2017
- Relief of Intractable Pruritus With NaloxoneArchives of Dermatology, 1979